Blood vessel and heart strength tests in AML patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Injuries & trauma clinical trials.
This study looks at how well your blood vessels and heart pumping ability work in people with acute myeloid leukemia (AML) receiving certain chemotherapy. It may help doctors better understand heart risk during treatment and tailor monitoring to you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) and will start anthracycline-containing chemotherapy
- You’re between 18 and 65 years old
- Your heart ultrasound shows pumping strength (left ventricular ejection fraction) above 50% before chemo
- You have no current signs of heart failure
- You can understand and sign consent to take part in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps people with newly diagnosed acute myeloid leukemia (AML) by closely monitoring their heart health during chemotherapy. It aims to detect any early heart problems caused by treatment so they can be managed sooner.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This study looks at how well your blood vessels work (“vasoregulation”) in people with chronic myeloid leukemia (CML) while taking bosutinib. The goal is to understand vascular changes and how they relate to treatment in CML.
This Phase 2 study tests whether a blood-pressure medicine plan (a beta blocker plus lisinopril) can protect the heart in people newly diagnosed with acute myeloid leukemia (AML) who are starting anthracycline chemotherapy. It looks at heart safety by requiring a good heart scan before treatment and careful medication eligibility.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.